This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme 관리

관리 기준 확인 2/4

주요 정보

Grant Bogle

최고 경영자

US$3.0m

총 보상

CEO 급여 비율	9.9%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	10.2yrs

최근 관리 업데이트

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12

Epizyme Q3 2020 Earnings Preview

Nov 05

CEO 보상 분석

Grant Bogle 의 보수는 Epizyme 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2022	n/a	n/a	-US$208m
Mar 31 2022	n/a	n/a	-US$236m
Dec 31 2021	US$3m	US$299k	-US$251m
Sep 30 2021	n/a	n/a	-US$267m
Jun 30 2021	n/a	n/a	-US$257m
Mar 31 2021	n/a	n/a	-US$251m
Dec 31 2020	US$196k	n/a	-US$232m
Sep 30 2020	n/a	n/a	-US$222m
Jun 30 2020	n/a	n/a	-US$202m
Mar 31 2020	n/a	n/a	-US$192m
Dec 31 2019	US$309k	n/a	-US$173m

보상 대 시장: Grant 의 총 보상 ($USD 3.01M )은 US 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Grant 의 보상이 증가했습니다.

CEO

Grant Bogle (64 yo)

less than a year

테뉴어

US$3,011,807

보상

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

리더십 팀

이름	위치	테뉴어	보상	소유권
Grant Bogle	President	less than a year	US$3.01m	데이터 없음
Jeffery Kutok	Chief Scientific Officer	2.3yrs	US$2.86m	0.0080% $ 19.9k
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jerald Korn	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Joseph Beaulieu	Senior VP	4.1yrs	데이터 없음	0.0058% $ 14.3k
Craig West	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
John Weidenbruch	Senior VP	no data	데이터 없음	데이터 없음
Tanja Weber	Chief Business Officer	3.6yrs	데이터 없음	데이터 없음
Mark De Rosch	Chief Regulatory Officer	2.8yrs	데이터 없음	데이터 없음
Rebecca Mehrwerth	Senior VP & Head of Commercial	less than a year	데이터 없음	데이터 없음
Christoph Diefenbach	Laboratory Manager of Research & Development	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: EPZM 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Grant Bogle	President	2.9yrs	US$3.01m	데이터 없음
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	데이터 없음	데이터 없음
George Daley	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Mott	Independent Chairman	12.7yrs	US$370.00k	0.19% $ 474.0k
Carl Goldfischer	Independent Director	12.9yrs	US$350.00k	0.0030% $ 7.4k
Christopher Walsh	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kenneth Bate	Independent Director	7.7yrs	US$330.94k	0% $ 0
Bruce Chabner	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ronald Evans	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joel Huff	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Steven Henikoff	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음

10.2yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: EPZM 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.2 년).

This company listing is no longer active

Epizyme 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Independent Chairman recently bought US$500k worth of stock

Independent Director recently bought US$60k worth of stock

Epizyme, Inc. Announces Executive Promotions

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Epizyme, Inc. Announces Executive Promotions

New 90-day low: US$10.34

Epizyme Q3 2020 Earnings Preview

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: US$11.52

New 90-day low - US$12.00

New 90-day low - US$12.13

First half earnings released

New 90-day low - US$13.84

CEO 보상 분석